MDB Capital/Media
Press Releases
MDB Capital and the companies it backs make the news because of their revolutionary approaches to solving global challenges. If you have needs beyond these resources, please contact [email protected]
MDB Capital Holdings Provides First Quarter 2025 Update
Management to Host Conference Call Today at 4:30 p.m. ET Addison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, today provides an...
New PatentVest Pulse Report Reveals IP Gaps in Billion-Dollar Humanoid Robotics Startups
Despite rising valuations, most humanoid robotics startups remain underprotected—leaving long-term value at risk Dallas, TX, May 14, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest...
MDB Capital Holdings to Host First Quarter 2025 Results Conference Call on Wednesday May 21, 2025, at 4:30 p.m. Eastern Time
Addison, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Wednesday May 21, 2025 at 4:30 p.m....
New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market
Designed for investors, board members, and CEOs, the latest PatentVest Pulse offers a strategic view of who’s winning—and why—in the emerging BCI market Dallas, TX, April 01, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy...
MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update
Management to Host Conference Call Today at 4:30 p.m. ET Addison, TX, March 31, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an...
MDB Capital Holdings to Host Fourth Quarter and Full Year 2024 Results Conference Call on Monday March 31, 2025, at 4:30 p.m. Eastern Time
Addison, TX, March 24, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Monday March 31, 2025 at 4:30 p.m. Eastern...
New PatentVest Pulse Report Reveals Transformative Trends in the AI Data Center Patent Race
China accounts for 77% of all AI data center patent filings globally, with five of the top patent holders hailing from China - underlining its dominant position in next-generation AI infrastructure Dallas, TX, March 05, 2025 (GLOBE NEWSWIRE) -- Today, PatentVest, a...
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering
Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will...
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
Rebranding Invizyne Technologies, Inc to eXoZymes Inc. Changing NASDAQ ticker from IZTC to EXOZ Introducing but not trademarking “exozymes” as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a...
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025. Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce...
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and Drug...
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
First cable-free, ambulatory ECG that captures the heart’s electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG...